We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical's adjusted EPS jumped 25% to $3, while revenue rose 22% to just over $3 billion.
Operating margin reached 42%, while higher R&D spending supports AI features and new robotic platforms.
A $450 million litigation settlement drove GAAP net income lower despite strong adjusted profitability.
Intuitive Surgical (ISRG - Free Report) reported strong adjusted earnings growth in the third quarter of 2026, supported by expanding adoption of its robotic platforms and improved operating efficiency. Adjusted earnings per share increased 25% year over year to $3, while revenue grew 22% to just over $3 billion. The company reported an adjusted operating margin of 42%, or 41% excluding a one-time $28 million tariff refund. The margin improvement reflects underlying business strength, providing Intuitive Surgical with room to fund product development while maintaining robust profitability.
ISRG continues to invest in innovation, supported by 18% growth in operating expenses led by higher variable compensation, headcount and prototype costs as several development programs advanced. Research and development expenses increased faster than selling, general and administrative expenses, indicating that Intuitive Surgical is prioritizing innovation rather than simply maximizing near-term margins. Management reiterated its intention to continue investing in existing and new platforms and advancing artificial intelligence (AI) capabilities. These initiatives include digital and AI features for da Vinci 5, such as a voice-activated interface and automated fourth-arm control. The company is also developing new instrumentation and expanding platform capabilities, including programs for its Ion system.
The distinction between adjusted and reported profitability is important. Although adjusted profit gained significantly, reported profitability declined during the third quarter. GAAP net income declined to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier, reflecting a $450 million litigation settlement subject to court approval. Thus, the 25% increase in adjusted EPS better captures operating performance before this settlement's impact.
Intuitive Surgical's results suggest that innovation-led growth is supporting strong adjusted profitability, while elevated R&D spending represents a deliberate investment in future differentiation and market expansion.
Peer Updates
Other medical device makers, such as Stryker (SYK - Free Report) and Medtronic (MDT - Free Report) , have also delivered strong earnings growth in their last reported quarter, on the back of strong fundamentals.
Stryker’s adjusted EPS increased 10.3% year over year to $3.52 in the third quarter, driven primarily by gross margin expansion and disciplined expense management. Adjusted gross margin improved 40 basis points (bps) to 65.4%, benefiting from operational efficiencies and a net tariff benefit. The adjusted operating margin expanded 60 bps to 26.2%. Strength in Endoscopy, Medical and Orthopaedics’ Mako business supported sales growth. However, EPS growth faces pressure from softer hip and knee procedures, affordability concerns and increased pre-authorization denials. Ongoing peripheral vascular supply constraints and commercial execution challenges following a cyber incident and SAP implementation also remain concerns.
Medtronic reported adjusted EPS of $1.45 in the first quarter of fiscal 2027, improving 15.1% year over year. The EPS also exceeded the midpoint of the company’s guidance as well as analyst expectations by 6 cents. Earnings growth was supported by broad-based demand, strong performances in Cardiac Rhythm Management, Cranial & Spinal Technologies and Surgical, and a 10-bp expansion in adjusted operating margin. Cost efficiencies and disciplined pricing also supported profitability. However, unfavorable business mix, particularly from Diabetes and Cardiac Ablation Solutions, weighed on gross margin by 50 bps. Additionally, a favorable tax-rate impact was largely timing-related and expected to reverse later in the year.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 22.7% so far this year against 3.5% growth for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 35.82, above the industry average. But it is significantly lower than its five-year median of 66.62. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.
Image: Shutterstock
ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) reported strong adjusted earnings growth in the third quarter of 2026, supported by expanding adoption of its robotic platforms and improved operating efficiency. Adjusted earnings per share increased 25% year over year to $3, while revenue grew 22% to just over $3 billion. The company reported an adjusted operating margin of 42%, or 41% excluding a one-time $28 million tariff refund. The margin improvement reflects underlying business strength, providing Intuitive Surgical with room to fund product development while maintaining robust profitability.
ISRG continues to invest in innovation, supported by 18% growth in operating expenses led by higher variable compensation, headcount and prototype costs as several development programs advanced. Research and development expenses increased faster than selling, general and administrative expenses, indicating that Intuitive Surgical is prioritizing innovation rather than simply maximizing near-term margins. Management reiterated its intention to continue investing in existing and new platforms and advancing artificial intelligence (AI) capabilities. These initiatives include digital and AI features for da Vinci 5, such as a voice-activated interface and automated fourth-arm control. The company is also developing new instrumentation and expanding platform capabilities, including programs for its Ion system.
The distinction between adjusted and reported profitability is important. Although adjusted profit gained significantly, reported profitability declined during the third quarter. GAAP net income declined to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier, reflecting a $450 million litigation settlement subject to court approval. Thus, the 25% increase in adjusted EPS better captures operating performance before this settlement's impact.
Intuitive Surgical's results suggest that innovation-led growth is supporting strong adjusted profitability, while elevated R&D spending represents a deliberate investment in future differentiation and market expansion.
Peer Updates
Other medical device makers, such as Stryker (SYK - Free Report) and Medtronic (MDT - Free Report) , have also delivered strong earnings growth in their last reported quarter, on the back of strong fundamentals.
Stryker’s adjusted EPS increased 10.3% year over year to $3.52 in the third quarter, driven primarily by gross margin expansion and disciplined expense management. Adjusted gross margin improved 40 basis points (bps) to 65.4%, benefiting from operational efficiencies and a net tariff benefit. The adjusted operating margin expanded 60 bps to 26.2%. Strength in Endoscopy, Medical and Orthopaedics’ Mako business supported sales growth. However, EPS growth faces pressure from softer hip and knee procedures, affordability concerns and increased pre-authorization denials. Ongoing peripheral vascular supply constraints and commercial execution challenges following a cyber incident and SAP implementation also remain concerns.
Medtronic reported adjusted EPS of $1.45 in the first quarter of fiscal 2027, improving 15.1% year over year. The EPS also exceeded the midpoint of the company’s guidance as well as analyst expectations by 6 cents. Earnings growth was supported by broad-based demand, strong performances in Cardiac Rhythm Management, Cranial & Spinal Technologies and Surgical, and a 10-bp expansion in adjusted operating margin. Cost efficiencies and disciplined pricing also supported profitability. However, unfavorable business mix, particularly from Diabetes and Cardiac Ablation Solutions, weighed on gross margin by 50 bps. Additionally, a favorable tax-rate impact was largely timing-related and expected to reverse later in the year.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 22.7% so far this year against 3.5% growth for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 35.82, above the industry average. But it is significantly lower than its five-year median of 66.62. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
ISRG currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.